PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Alfredo Addeo, Giuseppe Luigi Banna


Immune checkpoint inhibitors (ICPIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) axis have dramatically expanded the therapeutic armamentarium for non-small cell lung cancer (NSCLC) and are now standard treatments for patients with advanced disease (1).